Market Research Logo

Congenital Hyperinsulinism Pipeline Insight, 2019

Congenital Hyperinsulinism Pipeline Insight, 2019

Congenital Hyperinsulinism (CHI) (Neonatal Hyperinsulinism)

Overview:
Congenital Hyperinsulinism (CHI) - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Congenital Hyperinsulinism (CHI) Understanding
Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Congenital hyperinsulinism, refers to a clinically, genetically and morphologically heterogeneous group of disorders associated with dysregulated insulin secretion. The remarkable progress has been made in the diagnosis and management of CHI, which has directly translated into improved neurological outcomes for patients. This improvement in the understanding of the pathogenesis of CHI and the development of diagnostic modalities have helped in deciding the optimal management strategy for each patient.
Congenital Hyperinsulinism (CHI) Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Congenital Hyperinsulinism targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Congenital Hyperinsulinism pipeline report covers 5+ companies. Some of the key players include Zealand Pharma (Dasiglucagon), Rezolute (RZ358) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Congenital Hyperinsulinism (CHI) Analytical Perspective by DelveInsight
• In-depth Congenital Hyperinsulinism Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Congenital Hyperinsulinism Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
• The Congenital Hyperinsulinism report provides an overview of therapeutic pipeline activity for Congenital Hyperinsulinism across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Congenital Hyperinsulinism therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Congenital Hyperinsulinism Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Congenital Hyperinsulinism
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Congenital Hyperinsulinism to formulate effective R&D strategies
• Assess challenges and opportunities that influence Congenital Hyperinsulinism R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Congenital Hyperinsulinism in licensing and out licensing strategies by identifying prospective partners with progressing projects for Congenital Hyperinsulinism to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugsPlease Note: The report will be delivered in 2-3 business days upon order confirmation.


1. Report Introduction
2. Congenital Hyperinsulinism (CHI) (Neonatal Hyperinsulinism)
2.1. Congenital Hyperinsulinism(CHI) Disease Overview
2.2. Congenital Hyperinsulinism (CHI) History
2.3. Congenital Hyperinsulinism (CHI) Symptoms
2.4. Congenital Hyperinsulinism (CHI) Causes
2.5. Congenital Hyperinsulinism (CHI) Pathophysiology
2.6. Congenital Hyperinsulinism (CHI) Diagnosis
2.6.1. Diagnostic Guidelines
3. Congenital Hyperinsulinism(CHI) Current Treatment Patterns
3.1. Treatment Guidelines
4. Congenital Hyperinsulinism(CHI) - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Congenital Hyperinsulinism companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Congenital Hyperinsulinism Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Congenital Hyperinsulinism Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Congenital Hyperinsulinism Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Congenital Hyperinsulinism(CHI) -Products Analysis
6.1. Product Profiles
6.1.1. Dasiglucagon - Zealand Pharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. RZ358- Rezolute
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. Recent Technologies
8. Congenital Hyperinsulinism Key Companies
8.1. XOMA
8.2. Zealand Pharma
8.3. XERIS Pharmaceutical
8.4. Adocia
8.5. Hanmi Pharmaceutical
9. Congenital Hyperinsulinism Key Products
9.1. RZ 358
9.2. Dasiglucagon
9.3. Glucagon
9.4. Recombinant human glucagon
9.5. HM 15136
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Congenital Hyperinsulinism - Unmet Needs
12. Congenital Hyperinsulinism - Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
TABLE 1 Diagnostic Guidelines
TABLE 2 Treatment Guidelines
TABLE 3 Assessment Summary
TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis
TABLE 5 Congenital Hyperinsulinism (CHI) Acquisition Analysis
TABLE 6 Assessment by Phase of Development
TABLE 7 Assessment by Product Type (Mono / Combination)
TABLE 8 Assessment by Stage and Product Type
TABLE 9 Assessment by Route of Administration
TABLE 10 Assessment by Stage and Route of Administration
TABLE 11 Assessment by Molecule Type
TABLE 12 Assessment by Stage and Molecule Type
TABLE 13 Assessment by MOA
TABLE 14 Assessment by Stage and MOA
TABLE 15 Late Stage Products (Phase-III)
TABLE 16 Mid Stage Products (Phase-II)
TABLE 17 Early Stage Products (Phase-I)
TABLE 18 Pre-clinical and Discovery Stage Products
TABLE 19 Inactive Products
TABLE 20 Dormant Products
TABLE 21 Discontinued Products
Figure 1 Disease Overview
Figure 2 History
Figure 3 Symptoms
Figure 4 Causes
Figure 5 Pathophysiology
Figure 6 Diagnostic Guidelines
Figure 7 Treatment Guidelines
Figure 8 Congenital Hyperinsulinism companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9 Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10 Congenital Hyperinsulinism (CHI) Acquisition Analysis
Figure 11 Assessment by Phase of Development
Figure 12 Assessment by Product Type (Mono / Combination)
Figure 13 Assessment by Stage and Product Type
Figure 14 Assessment by Route of Administration
Figure 15 Assessment by Stage and Route of Administration
Figure 16 Assessment by Molecule Type
Figure 17 Assessment by Stage and Molecule Type
Figure 18 Assessment by MOA
Figure 19 Assessment by Stage and MOA
Figure 20 Late Stage Products (Phase-III)
Figure 21 Mid Stage Products (Phase-II)
Figure 22 Early Stage Products (Phase-I)
Figure 23 Pre-clinical and Discovery Stage Products
Figure 24 Inactive Products
Figure 25 Dormant Products
Figure 26 Discontinued Products
Figure 27 Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook